A Service For Professionals Monday, September 25, 2017
Contact (202) 540-8337

Company News Today

A Service For Professionals Monday, September 25, 2017 11605 Sources 406,042,735 Articles 3,235,762 Readers
Contact (202) 540-8337

Breaking News

< >

Experienced Biotech Expert Becomes Formal Member of the BiOasis Team

November 23, 2009 (FinancialWire) — biOasis Technologies Inc. (TSX Venture: BTI) announced that Dr. Delara Karkan has been named as Senior Industry Scientific Advisor.

Dr. Karkan has over 10 years experience in drug development in the pharmaceutical and biotechnology industry and government. Dr. Karkan is currently Senior Science Advisor to the Office of Science and Risk Management, Health Products and Food branch, Canada, acting as a collaborator and advisor to the Food and Drug Administration Nanotechnology task. She has served as Deputy director in the Biologics and Genomic Therapy directorate at Health Canada where she is responsible for the Preclinical safety unit. In addition, she has advised companies on developmental processes involving nanotechnology based products. Dr. Karkan has also served as director, Preclinical Research and Development with Labopharm Pharma Inc., as Senior Pharmacokinetist with MDS Pharma Sciences Clinical Research in Montreal and Germany, as a Toxicology Consultant at Vancouver General Imaging Centre, and as a Research Scientist and then Group Leader, Pharmacology at Synapse Technologies Inc. where she worked on the p97 technology now owned by biOasis.

Karkan obtained her Ph.D. from the University of British Columbia in Pharmacology and Therapeutics and is an American Board exam toxicologist (Diplomat of the American board of Toxicology). She obtained her M.Sc. in Biotechnology from The University of London, U.K. and her B.Sc. in Pharmacy from The University of Uppsala Sweden. Dr. Karkan has also passed the Patent Agent Exam of the Intellectual Property Institute of Canada. Dr. Karkan is a member of the American Pharmaceutical Association of Canada, the American Pharmaceutical Association, the Intellectual Property Institute of Canada and the FDA international nanotechnology team.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Powered by EIN Presswire